

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/511,341	08/25/2005	Katsutoshi Sasaki	BJS-4093-8 3748		
23117 NILYON & VA	23117 7590 10/09/2007 NIXON & VANDERHYE, PC			EXAMINER	
901 NORTH GLEBE ROAD, 11TH FLOOR			VOGEL, NANCY S		
ARLINGTON	VA 22203		ART UNIT PAPER NUMBER		
			1636		
			MAIL DATE	DELIVERY MODE	
			10/09/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
Office Action Summary		10/511,341	SASAKI ET AL.			
		Examiner	Art Unit			
	·	Nancy T. Vogel	1636			
Period fo	The MAILING DATE of this communication app or Reply	pears on the cover sheet with the c	orrespondence address			
WHIC - Exter after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REPL' CHEVER IS LONGER, FROM THE MAILING Donsions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. The period for reply is specified above, the maximum statutory period of the reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status	*					
1)□	Responsive to communication(s) filed on					
•	·	action is non-final.				
,—	· <del></del>					
<i>,</i> —	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Dispositi	on of Claims					
4)⊠ Claim(s) <u>1-108</u> is/are pending in the application.						
-	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6)	6) ☐ Claim(s) is/are rejected.					
7)	Claim(s) is/are objected to.					
8)🖂	Claim(s) 1-108 are subject to restriction and/or	election requirement.				
Applicati	on Papers					
9) 🗆	The specification is objected to by the Examine	er.	•			
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority u	inder 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
<ul><li>1. Certified copies of the priority documents have been received.</li><li>2. Certified copies of the priority documents have been received in Application No</li></ul>						
	3. Copies of the certified copies of the prior					
	application from the International Bureau	•	a in this National Stage			
* S	see the attached detailed Office action for a list		d.			
Attachmen		,, <del>–</del>	(DTO 448)			
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) Linterview Summary Paper No(s)/Mail Da				
3) Inform	nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	5) Notice of Informal P 6) Other:				

Art Unit: 1636

## **DETAILED ACTION**

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-26, 53-67, 78-92 drawn to a method of isolating DNA encoding a peptide capable of acting as an agonist.

Group II, claim(s) 27-35, drawn to a cell line derived from hypothalamus.

Group III, claim(s) 36-52, drawn to method for producing a peptide.

Group IV, claim(s) 68-77, drawn to a cell lined derived from a B-cell line.

Group V, claim(s) 93- 95, drawn to a constitutively activated mutant G-protein coupled receptor.

Group VI, claim(s) s 96, drawn to a method for screening or isolating an antagonist from MC1R.

Group VII, claim(s) 97, drawn to a method for screening an antagonist for GPR43.

Group VIII, claim(s) 98,, drawn to a method for screening an antagonist from GPR41.

Group IX, claim(s) 99, drawn to a method for screening an antagonist for G10d.

Group X, claim(s) 100-102, drawn to a method for isolating an agonist for a G-protein coupled receptor.

Group XI, claim(s) 103, drawn to a method of isolating an antagonist or inverse agonist for a G-protein coupled receptor.

Application/Control Number: 10/511,341

Art Unit: 1636

Group XII, claim(s) 104, 105, drawn to a method of isolating an activator or inhibitor for a peptide.

Group XIII, claim(s) 106-108, drawn to a host vector system.

The inventions listed as Groups I-XIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Inventions of Groups I, III, VI-XII are directed to related methods. The related inventions are distinct if the (1) the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect; (2) the inventions do not overlap in scope, i.e., are mutually exclusive; and (3) the inventions as claimed are not obvious variants. See MPEP § 806.05(j). In the instant case, the inventions as claimed recite different method steps and yield different results. Furthermore, the inventions as claimed do not encompass overlapping subject matter and there is nothing of record to show them to be obvious variants.

Inventions of Groups II and IV, V, are directed to related products. The related inventions are distinct if the (1) the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect; (2) the inventions do not overlap in scope, i.e., are mutually exclusive; and (3) the inventions as claimed are not obvious variants. See MPEP § 806.05(j). In the instant case, the inventions as claimed have a different structure and function, and are not obvious variants. Furthermore, the inventions as claimed do not encompass overlapping subject matter and there is nothing of record to show them to be obvious variants.

Application/Control Number: 10/511,341

Art Unit: 1636

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/511,341

Art Unit: 1636

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nancy T. Vogel whose telephone number is (571) 272-0780. The examiner can normally be reached on 7:00 - 3:30, Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached on (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

NV 10/1/07

NANCY VOGEL

Page 5